Claims for Patent: 9,896,681

Summary for Patent: 9,896,681

Title:	Genetic regulation of bone and cells by electromagnetic stimulation fields and uses thereof
Abstract:	The present invention provides methods to modify the genetic regulation of mammalian tissue, bone, cells or any combination thereof by preferential activation, up-regulation and/or down-regulation. The method comprises steps of tuning the predetermined profiles of one or more time-varying stimulation fields by manipulating the B-Field magnitude, rising slew rate, rise time, falling slew rate, fall time, frequency, wavelength, and duty cycle, and exposing mammalian cells or tissues to one or more tuned time-varying stimulation fields with predetermined profiles. Examples of mammalian cells or tissues are chondrocytes, osteoblasts, osteocytes, osteoclasts, nucleus pulposus, associated tissue, or any combination. The resulted modification on gene regulation of these cells, tissues or bones may promote the retention, repair of and reduction of compromised mammalian cartilage, bone, and associated tissue.
Inventor(s):	Goodwin; Thomas J. (Kemah, TX), Shackelford; Linda C. (Webster, TX)
Assignee:	The United States of America as represented by the National Aeronautics and Space Administration (Washington, DC)
Application Number:	14/445,995
Patent Claims:	1. A method to up-regulate or down-regulate an expression level of human genes of interest, comprising the steps of: positioning a time-varying stimulation field generating apparatus proximate to a sample of human chondrocyte cells or human osteoblast cells or a combination thereof; and generating, via said apparatus, a time-varying stimulation field with a B-Field magnitude of about 0.059 G or 0.65 G and a frequency of about 10 Hz for the human chondrocyte cells or a B-Field magnitude of about 0.65 G and a frequency of about 10 Hz or 15 Hz for the human osteoblast cells, a rising slew rate of about 2.0 kG/s to about 4.5 kG/s, a rise time, a falling slew rate of about 4.5 kG/s to about 15.5 kG/s, a fall time, a wavelength of about 500 ms, a duty cycle of about 80% or 30%, and a sample exposure time of 720 hours predetermined for upregulation or down-regulation of the expression level of the human genes of interest in the sample. 2. The method of claim 1, wherein said time-varying stimulation field generating apparatus comprises: a power source; a control component operably connected to said power source; and a transmission component operably connected to said control component and said power source. 3. The method of claim 1, wherein the mammalian genes of interest for said human chondrocyte cells are a Wnt signaling gene, forkhead box gene, a sex determining region Y Sry-related high mobility group box gene, a parathyroid hormone gene, a transforming growth factor beta super gene, a latent transforming growth factor gene, an integrin gene, a interleukin gene, a thrombospodin gene, a laminin gene, a proteoglycan gene, a collagen gene, an insulin gene, a disintegrin and metalloproteinase gene, an actin gene, a catenin gene and a cadherin super gene. 4. The method of claim 1, wherein the mammalian genes of interest for said human osteoblast cells are a forkhead box gene, a parathyroid hormone gene, an integrin gene, a interleukin gene, a thrombospodin gene, a laminin gene, a proteoglycan gene, an osteoglycin gene, a collagen gene, an insulin gene, a disintegrin and metalloproteinase gene, a disintegrin and metalloproteinase with thrombospondin motifs gene, a matrix metallopeptidase gene, an actin gene, a catenin gene, a cadherin super gene, a B-cell lymphoma gene, a calmodulin calcium-modulated gene, a calumenin gene, a cathepsin gene, a clusterin, cytochrome P 450 super gene, an endoglin gene, a fibrillin gene, a fibroblast growth factor gene, a leptin gene, a mitogen-activated protein kinase activated protein kinase gene, a muscle segment homeobox gene, a neurogenic locus notch homolog protein gene, a peroxisome proliferator-activated receptors gene, a platelet derived growth factor gene, a reticulocalbin gene, a runt related transcription factors gene, a signal transducer and activator of transcription gene, a similar to mothers against decapentaplegic gene, a stanniocalcin gene, a superoxide dismutase gene, a syndecan gene, a tumor necrosis factor super gene, an AKT/protein kinase B signaling gene, and an importin gene. 5. The method of claim 2, wherein said predetermined time-varying stimulation field is in the form of a substantially square, biphasic waveform. 6. The method of claim 1, wherein said rise time is between about 125 .mu.s to 1 ms. 7. The method of claim 1, wherein said fall time is between about 125 .mu.s to 1 ms. 8. The method of claim 1, further comprising the step of contacting said human chondrocyte cells or human osteoblast cells with Vitamin D, Vitamin K or a combination of Vitamin D and Vitamin K. 9. A method of activating mammalian human genes associated with bone formation, comprising the steps of: generating at least one time-varying stimulation field in the form of a substantially square, biphasic waveform by using a time-varying stimulation field generating apparatus; manipulating a B-Field magnitude, rising slew rate, rise time, falling slew rate, fall time, frequency, wavelength, duty cycle, sample exposure time or time sequences, or a combination thereof of the at least one time varying stimulation field to values predetermined for activating the mammalian genes; exposing samples of mammalian cells associated with bone formation to said at least one time varying stimulation field manipulated for activation of the mammalian genes; and contacting said mammalian cells associated with bone formation with Vitamin D, Vitamin K or a combination of Vitamin D and Vitamin K at the exposing step. 10. The method of claim 9, wherein said time varying stimulation field generating apparatus comprises: a power source; a control component operably connected to said power source; and a transmission component operably connected to said control component and said power source. 11. The method of claim 9, wherein said mammalian genes are bone morphogenetic protein family genes, actin family genes, thrombospondin family genes, lamanin family genes, proteoglycan family genes, collagen family genes, tumor necrosis factor genes family, transforming growth factor family genes, actin/cytoskeleton related family genes or a combination thereof. 12. The method of claim 9, wherein said B-Field magnitude is between about 0.6 G to about 50 G. 13. The method of claim 9, wherein said B-Field frequency is from about 10 Hz to about 16 Hz. 14. The method of claim 9, wherein said rise time is from about 0.75 ms to about 1 ms and said rising slew rate is from about 2.0 kG/s to about 4.5 kG/s. 15. The method of claim 9, wherein said fall time is from about 125 .mu.s to about 300 .mu.s and said falling slew rate from about 4.5 kG/s to about 15.5 kG/s. 16. The method of claim 9, wherein said duty cycle from about 65% to about 80%. 17. The method of claim 9, wherein said B-field magnitude is about 0.65 G. 18. The method of claim 9, wherein said frequency is about 10 Hz. 19. The method of claim 9, wherein said cellular samples are damaged cartilage, bone or a combination thereof.

Details for Patent 9,896,681

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-02-26